Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 825375, 11 pages
http://dx.doi.org/10.1155/2013/825375
Review Article

Hepatitis C Virus Infection: Looking for Interferon Free Regimens

Internal Medicine-Infectious Diseases Department, Hospital Son Llàtzer, Carretera de Manacor, Km 4, 07198 Palma de Mallorca, Spain

Received 7 February 2013; Accepted 4 March 2013

Academic Editors: H. C. Lin and S.-N. Lu

Copyright © 2013 J. González-Moreno and A. Payeras-Cifre. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “Evolving epidemiology of hepatitis C virus,” Clinical Microbiology and Infection, vol. 17, no. 2, pp. 107–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Wise, S. Bialek, L. Finelli, B. P. Bell, and F. Sorvillo, “Changing trends in hepatitis C-related mortality in the United States, 1995–2004,” Hepatology, vol. 47, no. 4, pp. 1128–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. European Paediatric Hepatitis C Virus Network, “Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 108, no. 4, pp. 371–377, 2001. View at Google Scholar
  4. M. J. Alter, R. J. Gerety, and L. A. Smallwood, “Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population,” Journal of Infectious Diseases, vol. 145, no. 6, pp. 886–893, 1982. View at Google Scholar · View at Scopus
  5. L. B. Seeff, “Natural history of hepatitis C,” American Journal of Medicine, vol. 107, no. 6, pp. 10S–15S, 1999. View at Google Scholar
  6. T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle, “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132, no. 4, pp. 296–305, 2000. View at Google Scholar · View at Scopus
  7. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. N. Assis and J. K. Lin, “New phamacotherapy for hepatitis C,” Clinical Pharmacology & Therapeutics, vol. 92, no. 3, pp. 294–305, 2012. View at Google Scholar
  10. H. R. Rosen, “Chronic hepatitis C infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2429–2438, 2011. View at Publisher · View at Google Scholar
  11. L. Chemello, L. Cavalletto, E. Bernardinello, M. Guido, P. Pontisso, and A. Alberti, “The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C,” Journal of Hepatology, Supplement, vol. 23, supplement 2, pp. 8–12, 1995. View at Google Scholar · View at Scopus
  12. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. L. D. Pedicone, C. A. Brass, J. K. Albrecht et al., “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,” The New England Journal of Medicine, vol. 361, no. 6, pp. 580–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Laguno, C. Cifuentes, J. Murillas et al., “Randomized trial comparing pegylated interferon -2b versus pegylated interferon -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients,” Hepatology, vol. 49, no. 1, pp. 22–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. di Martino, C. Richou, J. P. Cervoni et al., “Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future,” Hepatology, vol. 54, no. 3, pp. 789–800, 2011. View at Publisher · View at Google Scholar
  17. B. D. Lindenbach and C. M. Rice, “Unravelling hepatitis C virus replication from genome to function,” Nature, vol. 436, no. 7053, pp. 933–938, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Foy, K. Li, C. Wang et al., “Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease,” Science, vol. 300, no. 5622, pp. 1145–1148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. E. D. Brenndorfer, A. Brass, J. Soderholm et al., “Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production,” Gut, vol. 61, no. 4, pp. 589–596, 2012. View at Publisher · View at Google Scholar
  20. C. Hézode, N. Forestier, G. Dusheiko et al., “Telaprevir and peginterferon with or without ribavirin for chronic HCV infection,” The New England Journal of Medicine, vol. 360, no. 18, pp. 1839–1850, 2009. View at Publisher · View at Google Scholar
  21. J. G. McHutchison, G. T. Everson, S. C. Gordon et al., “Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 360, no. 18, pp. 1827–1838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. E. Sherman, S. L. Flamm, N. H. Afdhal et al., “Response-guided telaprevir combination treatment for hepatitis C virus infection,” The New England Journal of Medicine, vol. 365, no. 11, pp. 1014–1024, 2011. View at Publisher · View at Google Scholar
  24. S. Zeuzem, P. Andreone, S. Pol et al., “Telaprevir for retreatment of HCV infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2417–2428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. L. Pearlman, “Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care,” The Lancet Infectious Diseases, vol. 12, no. 9, pp. 717–728, 2012. View at Publisher · View at Google Scholar
  26. P. Y. Kwo, E. J. Lawitz, J. McCone et al., “Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial,” The Lancet, vol. 376, no. 9742, pp. 705–716, 2010. View at Publisher · View at Google Scholar
  27. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. B. R. Bacon, S. C. Gordon, E. Lawitz et al., “Boceprevir for previously treated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1207–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Sitole, M. Silva, L. Spooner, M. K. Comee, and M. Malloy, “Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials,” Clinical Therapeutics, vol. 35, no. 2, pp. 190–197, 2013. View at Publisher · View at Google Scholar
  30. T. Asselah and P. Marcellin, “Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow,” Liver International, vol. 32, supplement 1, pp. 88–102, 2012. View at Publisher · View at Google Scholar
  31. T. Kuntzen, J. Timm, A. Berical et al., “Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients,” Hepatology, vol. 48, no. 6, pp. 1769–1778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. W. P. Hofmann, E. Herrmann, C. Sarrazin, and S. Zeuzem, “Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms,” Liver International, vol. 28, no. 10, pp. 1332–1343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Thomas, J. J. Feld, Q. Li, Z. Hu, M. W. Fried, and T. J. Liang, “Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models,” Hepatology, vol. 53, no. 1, pp. 32–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. G. McHutchison, M. P. Manns, A. J. Muir et al., “Telaprevir for previously treated chronic HCV infection,” The New England Journal of Medicine, vol. 362, no. 14, pp. 1292–1303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Poordad, E. Lawitz, M. L. Shiffman et al., “Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C,” Hepatology, vol. 52, no. 4, pp. 1208–1215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Marcellin, R. G. Gish, N. Gitlin et al., “Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients,” Journal of Hepatology, vol. 52, no. 1, pp. 32–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Zeuzem, P. Buggisch, K. Agarwal et al., “The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C,” Hepatology, vol. 55, no. 3, pp. 749–758, 2012. View at Publisher · View at Google Scholar
  38. E. J. Gane, C. A. Stedman, R. H. Hyland et al., “Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,” The New England Journal of Medicine, vol. 368, no. 1, pp. 34–44, 2013. View at Publisher · View at Google Scholar
  39. D. R. Nelson, E. J. Gane, I. M. Jacobson, A. M. di Bisceglie, K. Alves, and M. J. Koziel, “VX-222/telaprevir in combination with peginterferon-alpha-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis,” Hepatology, vol. 54, p. 1435, 2011, abstract LB-14. View at Google Scholar
  40. S. Zeuzem, S. Arora, B. Bacon et al., “Pegylated interferon-lambda (PegIFN-λ) shows superior viral response with improved safety and tolerability versus pegIFN-a-2a in HCV patients, (G1/2/3/4): EMERGE phase IIb through week 12,” in Proceedings of the 46th Annual Meeting of the European Association for the Study of the Liver (EASL '11), Berlin, Germany, April 2011, http://www.natap.org/2011/EASL/EASL_29.htm.
  41. J. Friborg, S. Levine, C. Chen, A. K. Sheaffer, S. Chaniewski, and F. McPhee, “Combination of interferon lambda with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication,” Antimicrob Agents Chemother, vol. 57, no. 3, pp. 1312–1322, 2013. View at Publisher · View at Google Scholar
  42. L. Malmgaard, “Induction and regulation of IFNs during viral infections,” Journal of Interferon and Cytokine Research, vol. 24, no. 8, pp. 439–454, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. T. L. Kieffer, C. Sarrazin, J. S. Miller et al., “Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients,” Hepatology, vol. 46, no. 3, pp. 631–639, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Sarrazin, C. Hézode, S. Zeuzem, and J. M. Pawlotsky, “Antiviral strategies in hepatitis C virus infection,” Journal of Hepatology, vol. 56, supplement 1, pp. S88–S100, 2012. View at Google Scholar
  45. C. Sarrazin and S. Zeuzem, “Resistance to direct antiviral agents in patients with hepatitis C virus infection,” Gastroenterology, vol. 138, no. 2, pp. 447–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. E. J. Gane, S. K. Roberts, C. A. M. Stedman et al., “Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial,” The Lancet, vol. 376, no. 9751, pp. 1467–1475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. McCown, S. Rajyaguru, S. Kular, N. Cammack, and I. Najera, “Suppression of in vitro resistance development after treatment of the HCV replicon with NS3/4a inhibitor ITMN-191 (R7227) in combination with nucleoside inhibitor R7128 or R1626,” Journal of Hepatology, vol. 50, p. S349, 2009. View at Google Scholar
  48. S. Zeuzem, T. Asselah, P. Angus et al., “Efficacy of the protease inhibitor BI, 201335, polymerase inhibitor BI, 207127, and ribavirin in patients with chronic HCV infection,” Gastroenterology, vol. 141, no. 6, pp. 2047–2055, 2011. View at Publisher · View at Google Scholar
  49. A. S. Lok, D. F. Gardiner, E. Lawitz et al., “Preliminary study of two antiviral agents for hepatitis C genotype 1,” The New England Journal of Medicine, vol. 366, no. 3, pp. 216–224, 2012. View at Publisher · View at Google Scholar
  50. F. McPhee, A. K. Sheaffer, J. Friborg et al., “Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032),” Antimicrobial Agents and Chemotherapy, vol. 56, no. 10, pp. 5387–5396, 2012. View at Publisher · View at Google Scholar
  51. K. Chayama, S. Takahashi, J. Toyota et al., “Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null-responders.,” Hepatology, vol. 55, no. 3, pp. 742–748, 2012. View at Publisher · View at Google Scholar
  52. Y. Suzuki, K. Ikeda, F. Suzuki et al., “Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options,” Journal of Hepatology, 2012. View at Publisher · View at Google Scholar
  53. E. Lawitz, M. Rodriguez-Torres, J. Denning et al., “Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA< LOD at Day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study),” Journal of Hepatology, vol. 54, supplement 1, p. S543, 2011, abstract 1370. View at Google Scholar
  54. M. Sulkowski, D. Gardiner, E. Lawitz et al., “Potent viral suppression with the alloralcombination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/−, ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3,” in Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 2012.
  55. Gilead Sciences, “Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment-naive hepatitis C patients: interim results reported from ELECTRON and QUANTUM studies,” 2012, http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1684792&highlight.
  56. F. Poordad, E. Lawitz, K. V. Kowdley et al., “Exploratory study of oral combination antiviral therapy for hepatitis C,” The New England Journal of Medicine, vol. 368, no. 1, pp. 45–53, 2013. View at Publisher · View at Google Scholar
  57. M. S. Sulkowski, R. D. Moore, S. H. Mehta, R. E. Chaisson, and D. L. Thomas, “Hepatitis C and progression of HIV disease,” Journal of the American Medical Association, vol. 288, no. 2, pp. 199–206, 2002. View at Google Scholar · View at Scopus
  58. V. Soriano, P. Labarga, A. Ruiz-Sancho, J. Garcia-Samaniego, and P. Barreiro, “Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin,” AIDS, vol. 20, no. 17, pp. 2225–2227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Berenguer, E. Rodríguez, P. Miralles et al., “Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus,” Clinical Infectious Diseases, vol. 55, no. 5, pp. 728–736, 2012. View at Publisher · View at Google Scholar
  60. D. Dieterich, V. Soriano, K. Shermann et al., “Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: 24-week treatment interim analysis,” Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI '12), Seattle, March 2012, abstract 46.
  61. J. Mallolas, S. Pol, A. Rivero et al., “Boceprevir plus peginterferon/ribavirin for the treatment of HIV-HCVcoinfected patients: end of treatment week 48 interim results,” in Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver (EASL '12), Barcelona, Spain, April 2012, abstract 366.
  62. M. Rodríguez-Torres, “Focus on drug interactions: the challenge of treating hepatitis C virus infection with directacting antiviral drugs in the HIV-positive patient,” Current Opinion in Infectious Diseases, vol. 26, no. 1, pp. 50–57, 2013. View at Google Scholar
  63. C. Wartelle-Bladou, G. le Folgoc, M. Bourlière, and L. Lecomte, “Hepatitis C therapy in non-genotype 1 patients: the near future,” Journal of Viral Hepatitis, vol. 19, no. 8, pp. 525–536, 2012. View at Google Scholar
  64. G. R. Foster, C. Hézode, J. P. Bronowicki et al., “Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections,” Gastroenterology, vol. 141, no. 3, pp. 881–889, 2011. View at Publisher · View at Google Scholar
  65. Y. Benhamou, J. Moussalli, V. Ratziu et al., “Activity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210,” Hepatology, vol. 52, pp. 719A–720A, 2010. View at Google Scholar
  66. T. I. Lin, O. Lenz, G. Fanning et al., “In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitory,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1377–1385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Moreno, T. Berg, T. Tanwandee et al., “Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study,” Journal of Hepatology, vol. 56, no. 6, pp. 1247–1253, 2012. View at Publisher · View at Google Scholar
  68. J. M. Gottwein, T. K. Scheel, T. B. Jensen, L. Ghanem, and J. Bukh, “Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses,” Gastroenterology, vol. 141, no. 3, pp. 1067–1079, 2011. View at Publisher · View at Google Scholar
  69. G. Everson, C. Cooper, C. Hezode et al., “Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/PEGIFN alfa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis,” Journal of Hepatology, vol. 56, p. S466, 2012. View at Google Scholar